← Antihypertensives × lipids

TrialDrug design, development and therapy2016

Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong).

Jin-Sun Park et al.PubMed ↗Full text ↗Publisher ↗

  • FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin)no clear effectLower LDL cholesterol, lower diastolic blood pressure.Nothing cleared the noise.

What the trial testedas reported · 162 people · 2016

Not counted

Probably lowered LDL cholesterol

−51.7percentage points−59.8 to −43.6

FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin) vs 40 mg olmesartan medoxomil

As reported

difference −51.7 %, 95% CI −59.8 to −43.6 · the paper's word: percentage change from baseline in low-density lipoprotein cholesterol levels

Not counted

Probably lowered diastolic blood pressure

−10.5−14.1 to −6.90

FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin) vs 20 mg rosuvastatin

As reported

difference −10.5, 95% CI −14.1 to −6.90 · the paper's word: change from baseline in diastolic blood pressure

Who was studied, and how

162people with hypertension, aged 20+, in this paper

The trial randomly assignedassigned by chance

FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin)
40 mg olmesartan medoxomil

Probably lowered LDL cholesterol−51.7

randomised

The trial randomly assignedassigned by chance

FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin)
20 mg rosuvastatin

Probably lowered diastolic blood pressure−10.5

randomised

the abstract, start to end

… P<0.0001), and the difference was -51.7% (4.1%) (95% confidence …

… mmHg, P<0.0001), and the difference was -10.5 (1.8) mmHg (95% confidence …

← favours treatmentfavours comparator →
could be chance
Percentage change from baseline in low-density lipoprotein cholesterol levelsFDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin) vs 40 mg olmesartan medoxomil
−51.7−59.8 to −43.6
Change from baseline in diastolic blood pressureFDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin) vs 20 mg rosuvastatin
−10.5−14.1 to −6.90
StatinsAntihypertensivesLipidsBlood pressure
1 / 4

11 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 27574399